Drugs for Herpes Labialis (Oral Herpes) Market Trends [2031]

Segments - Drugs for Herpes Labialis (Oral Herpes) Market By Product Type (Aciclovir, Valacyclovir, Famciclovir, Docosano), By Medication Type (Prescribed (Rx), OTC), By Dosage Forms (Ointments/Cream/Gels/Lip Balm , Medicines, Injections), By Routes of Administration (Topical, Oral, Parenteral ), and Region (North America, Europe, Asia Pacific, Latin America, Middle East & Asia) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

The market is driven by factors such as increasing prevaleThe global drugs for herpes labialis (oral herpes) market was valued at USD 1.05 Billion in 2022 and is projected to reach USD 1.57 Billion by 2031, expanding at a CAGR of 4.6% during the forecast period 2023-2031.nce of herpes labialis among children and adults across the globe, innovations in drug types and modes of action, soaring penetration of generics, frequent transformations in disease treatment, and growing consumer awareness.

However, stringent government regulations regarding drug approvals and lack of awareness and knowledge about herpes labialis are key restraints of this market.

Drugs for Herpes Labialis (Oral Herpes) Market Outlook

Increasing R&D is estimated to create lucrative opportunities in the near future. The emergence of novel therapies is boosting the growth of the market. Recent market trends include collaborations between market players and universities, and mergers & acquisitions among the leading companies.

On the basis of product types, the drugs for herpes labialis (oral herpes) market is segmented into aciclovir, valacyclovir, famciclovir, docosanol, and penciclovir. The acyclovir segment is estimated to hold a large share of the market during the forecast period, as these drugs are widely used and trusted due to their highly effective outcomes.

Valacyclovir is considered to be more effective than the previously used drugs such as aciclovir due to requirement of limited number of dosages, long-term effect on the infection, and immediate effect on virus infection; ,therefore the segment is anticipated to expand at a high CAGR of X.1% during the forecast period.

Drugs for Herpes Labialis (Oral Herpes) Market Type

Based of medication types, the drugs for herpes labialis (oral herpes) market is bifurcated into prescribed (Rx) and OTC. The prescribed (Rx) segment is projected to constitute a X4.8% share of the market by 2027 and is anticipated to expand at a CAGR of X.7% due to the increase in incidences of herpes labialis, which in turn, boosts the usage of the prescribed medication.

On the basis of dosage forms, the market is divided into ointments/creams/gels/lip balms, medicines, and injections. The medicines segment holds a major share of the market and is projected to expand at high CAGR, medicines are considered to be effective and have a high success rate of recovery. Ointments/creams/gels/lip balms are considered to be effective for instantly providing pain relief on the site of infections and is usually prescribed with the medicines to increase the rate of recovery. This, in turn, increases the demand for the ointments/creams/gels/lip balms.

On the basis of routes of administration, the drugs for herpes labialis (oral herpes) market is segregated into topical, oral, and parenteral. The oral segment holds a major share of the market and is projected to expand at a substantial CAGR during the forecast period, as it is a highly preferred method of consuming medications and is easy to consume. Oral medications are usually prescribed with the combination of topically administered drugs, which in turn, is expected to drive the demand for oral and topical medications with CAGR of X.8% and X.5%, respectively, during the forecast period.

Drugs for Herpes Labialis (Oral Herpes) Market Administration

In terms of regions, the global drugs for herpes labialis (oral herpes) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a promising region for the market. The market is this region constituted a X4.6% share of the global market in 2020.

The market in the region is projected to expand at a CAGR of X.4% during the forecast period due to the increase in the demand for drugs for herpes labialis, the presence of a well-developed pharmaceutical infrastructure for R&D activities, and the presence of major players in this region.The market in Asia Pacific is projected to expand at a CAGR of X.2% due to increased government spending, rising FDI policies, and growing incidences of the herpes labialis in the region.

Drugs for Herpes Labialis (Oral Herpes) Market Region

Drugs for Herpes Labialis (Oral Herpes) Market Report Attribute

Report Attribute	Report Details
Report Title	Drugs for Herpes Labialis (Oral Herpes) Market– Global Industry Analysis, Size, Share, Growth, Trends, and Forecast
Base Year	2022
Historical Data	2016–2021
Forecast Year	2023–2031
Growth Rate	4.6%
Market Value in 2022	USD 1.05 Billion
Regional scope	By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Asia)
Segments covered	By Product Type (Aciclovir, Valacyclovir, Famciclovir, Docosano), By Medication Type (Prescribed (Rx), OTC), By Dosage Forms (Ointments/Cream/Gels/Lip Balm , Medicines, Injections), By Routes of Administration (Topical, Oral, Parenteal), By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Asia)
Key Companies Profiled	Apotex Inc, Pfizer INC, Mylan N.V., Novartis AG, Teva Pharmaceutical Industries Ltd, Zydus Cadila, Hikma Pharmaceuticals PLC, Livzon, Torrent Pharmaceuticals Ltd, Blistex Inc

Segments

By Product Type

Aciclovir
Valacyclovir
Famciclovir
Docosano

By Medi cation Type:

Prescribed (Rx)
OTC

By Dosage Forms:

Ointments/Cream/Gels/Lip Balm
Medicines
Injections

By Routes of Administration:

Topical
Oral
Parenteral

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Asia

Key Players

Competitive Landscape

Key players in the market include Pfizer INC., Mylan N.V., Teva Pharmaceutical Industries Ltd. They are considered as key drug manufacturers in this market based on their investments in R&D, segmental revenue, regional presence, and supply chain management system.

Drugs for Herpes Labialis (Oral Herpes) Market Key Players

Drugs for Herpes Labialis (Oral Herpes) Market Key Players

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Drugs for Herpes Labialis Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
    4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Drugs for Herpes Labialis Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Drugs for Herpes Labialis Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Drugs for Herpes Labialis Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Drugs for Herpes Labialis Market Size & Forecast, 2017-2027
      4.5.1 Drugs for Herpes Labialis Market Size and Y-o-Y Growth
      4.5.2 Drugs for Herpes Labialis Market Absolute $ Opportunity
   4.6 Pricing Analysis & Forecast, By Product Type, 2017-2027
   4.7 Global Drugs for Herpes Labialis Market: Impact Of Key Regulations

Chapter 5 Global Drugs for Herpes Labialis Market Analysis and Forecast By Product Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product Type
      5.1.2 Basis Point Share (BPS) Analysis By Product Type
      5.1.3 Absolute $ Opportunity Assessment By Product Type
   5.2 Drugs for Herpes Labialis Market Size & Volume Forecast By Product Type
      5.2.1 Aciclovir
      5.2.2 Valacyclovir
      5.2.3 Famciclovir
      5.2.4 Docosano
   5.3 Market Attractiveness Analysis By Product Type

Chapter 6 Global Drugs for Herpes Labialis Market Analysis and Forecast By Medication Type
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Medication Type
      6.1.2 Basis Point Share (BPS) Analysis By Medication Type
      6.1.3 Absolute $ Opportunity Assessment By Medication Type
   6.2 Drugs for Herpes Labialis Market Size & Volume Forecast By Medication Type
      6.2.1 Prescribed
      6.2.2 OTC
   6.3 Market Attractiveness Analysis By Medication Type

Chapter 7 Global Drugs for Herpes Labialis Market Analysis and Forecast By Dosage Forms
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Dosage Forms
      7.1.2 Basis Point Share (BPS) Analysis By Dosage Forms
      7.1.3 Absolute $ Opportunity Assessment By Dosage Forms
   7.2 Drugs for Herpes Labialis Market Size & Volume Forecast By Dosage Forms
      7.2.1 Ointments/Cream/Gels/Lip Balm
      7.2.2 Medicines
      7.2.3 Injections
   7.3 Market Attractiveness Analysis By Dosage Forms

Chapter 8 Global Drugs for Herpes Labialis Market Analysis and Forecast By Routes of Administration
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By Routes of Administration
      8.1.2 Basis Point Share (BPS) Analysis By Routes of Administration
      8.1.3 Absolute $ Opportunity Assessment By Routes of Administration
   8.2 Drugs for Herpes Labialis Market Size & Volume Forecast By Routes of Administration
      8.2.1 Topical
      8.2.2 Oral
      8.2.3 Parenteral
   8.3 Market Attractiveness Analysis By Routes of Administration

Chapter 9 Global Drugs for Herpes Labialis Market Analysis and Forecast by Region
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities by Region
      9.1.2 Basis Point Share (BPS) Analysis by Region
      9.1.3 Absolute $ Opportunity Assessment by Region
   9.2 Drugs for Herpes Labialis Market Size Forecast by Region
      9.2.1 North America
      9.2.2 Europe
      9.2.3 Asia Pacific
      9.2.4 Latin America
      9.2.5 Middle East & Africa (MEA)
   9.3 Market Attractiveness Analysis by Region

Chapter 10 Coronavirus Disease (COVID-19) Impact
   10.1 Introduction
   10.2 Current & Future Impact Analysis
   10.3 Economic Impact Analysis
   10.4 Government Policies
   10.5 Investment Scenario

Chapter 11 North America Drugs for Herpes Labialis Analysis and Forecast
   11.1 Introduction
   11.2 North America Drugs for Herpes Labialis Market Size Forecast by Country
      11.2.1 U.S.
      11.2.2 Canada
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 North America Drugs for Herpes Labialis Market Size & Volume Forecast By Product Type
      11.6.1 Aciclovir
      11.6.2 Valacyclovir
      11.6.3 Famciclovir
      11.6.4 Docosano
   11.7 Basis Point Share (BPS) Analysis By Product Type
   11.8 Absolute $ Opportunity Assessment By Product Type
11.9 Market Attractiveness Analysis By Product Type
   11.10 North America Drugs for Herpes Labialis Market Size & Volume Forecast By Medication Type
      11.10.1 Prescribed
      11.10.2 OTC
   11.11 Basis Point Share (BPS) Analysis By Medication Type
   11.12 Absolute $ Opportunity Assessment By Medication Type
   11.13 Market Attractiveness Analysis By Medication Type
   11.14 North America Drugs for Herpes Labialis Market Size & Volume Forecast By Dosage Forms
      11.14.1 Ointments/Cream/Gels/Lip Balm
      11.14.2 Medicines
      11.14.3 Injections
   11.15 Basis Point Share (BPS) Analysis By Dosage Forms
   11.16 Absolute $ Opportunity Assessment By Dosage Forms
   11.17 Market Attractiveness Analysis By Dosage Forms
   11.18 North America Drugs for Herpes Labialis Market Size & Volume Forecast By Routes of Administration
      11.18.1 Topical
      11.18.2 Oral
      11.18.3 Parenteral
   11.19 Basis Point Share (BPS) Analysis By Routes of Administration
   11.20 Absolute $ Opportunity Assessment By Routes of Administration
   11.21 Market Attractiveness Analysis By Routes of Administration

Chapter 12 Europe Drugs for Herpes Labialis Analysis and Forecast
   12.1 Introduction
   12.2 Europe Drugs for Herpes Labialis Market Size Forecast by Country
      12.2.1 Germany
      12.2.2 France
      12.2.3 Italy
      12.2.4 U.K.
      12.2.5 Spain
      12.2.6 Russia
      12.2.7 Rest of Europe
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Europe Drugs for Herpes Labialis Market Size & Volume Forecast By Product Type
      12.6.1 Aciclovir
      12.6.2 Valacyclovir
      12.6.3 Famciclovir
      12.6.4 Docosano
   12.7 Basis Point Share (BPS) Analysis By Product Type
   12.8 Absolute $ Opportunity Assessment By Product Type
   12.9 Market Attractiveness Analysis By Product Type
   12.10 Europe Drugs for Herpes Labialis Market Size & Volume Forecast By Medication Type
      12.10.1 Prescribed
      12.10.2 OTC
   12.11 Basis Point Share (BPS) Analysis By Medication Type
   12.12 Absolute $ Opportunity Assessment By Medication Type
   12.13 Market Attractiveness Analysis By Medication Type
   12.14 Europe Drugs for Herpes Labialis Market Size & Volume Forecast By Dosage Forms
      12.14.1 Ointments/Cream/Gels/Lip Balm
      12.14.2 Medicines
      12.14.3 Injections
   12.15 Basis Point Share (BPS) Analysis By Dosage Forms
   12.16 Absolute $ Opportunity Assessment By Dosage Forms
   12.17 Market Attractiveness Analysis By Dosage Forms
   12.18 Europe Drugs for Herpes Labialis Market Size & Volume Forecast By Routes of Administration
      12.18.1 Topical
      12.18.2 Oral
      12.18.3 Parenteral
   12.19 Basis Point Share (BPS) Analysis By Routes of Administration
   12.20 Absolute $ Opportunity Assessment By Routes of Administration
   12.21 Market Attractiveness Analysis By Routes of Administration

Chapter 13 Asia Pacific Drugs for Herpes Labialis Analysis and Forecast
   13.1 Introduction
   13.2 Asia Pacific Drugs for Herpes Labialis Market Size Forecast by Country
      13.2.1 China
      13.2.2 Japan
      13.2.3 South Korea
      13.2.4 India
      13.2.5 Australia
      13.2.6 Rest of Asia Pacific (APAC)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Asia Pacific Drugs for Herpes Labialis Market Size & Volume Forecast By Product Type
      13.6.1 Aciclovir
      13.6.2 Valacyclovir
      13.6.3 Famciclovir
      13.6.4 Docosano
   13.7 Basis Point Share (BPS) Analysis By Product Type
   13.8 Absolute $ Opportunity Assessment By Product Type
   13.9 Market Attractiveness Analysis By Product Type
   13.10 Asia Pacific Drugs for Herpes Labialis Market Size & Volume Forecast By Medication Type
      13.10.1 Prescribed
      13.10.2 OTC
   13.11 Basis Point Share (BPS) Analysis By Medication Type
   13.12 Absolute $ Opportunity Assessment By Medication Type
   13.13 Market Attractiveness Analysis By Medication Type
   13.14 Asia Pacific Drugs for Herpes Labialis Market Size & Volume Forecast By Dosage Forms
      13.14.1 Ointments/Cream/Gels/Lip Balm
      13.14.2 Medicines
      13.14.3 Injections
   13.15 Basis Point Share (BPS) Analysis By Dosage Forms
   13.16 Absolute $ Opportunity Assessment By Dosage Forms
   13.17 Market Attractiveness Analysis By Dosage Forms
   13.18 Asia Pacific Drugs for Herpes Labialis Market Size & Volume Forecast By Routes of Administration
      13.18.1 Topical
      13.18.2 Oral
      13.18.3 Parenteral
   13.19 Basis Point Share (BPS) Analysis By Routes of Administration
   13.20 Absolute $ Opportunity Assessment By Routes of Administration
   13.21 Market Attractiveness Analysis By Routes of Administration

Chapter 14 Latin America Drugs for Herpes Labialis Analysis and Forecast
   14.1 Introduction
   14.2 Latin America Drugs for Herpes Labialis Market Size Forecast by Country
      14.2.1 Brazil
      14.2.2 Mexico
      14.2.3 Rest of Latin America (LATAM)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Latin America Drugs for Herpes Labialis Market Size & Volume Forecast By Product Type
      14.6.1 Aciclovir
      14.6.2 Valacyclovir
      14.6.3 Famciclovir
      14.6.4 Docosano
   14.7 Basis Point Share (BPS) Analysis By Product Type
   14.8 Absolute $ Opportunity Assessment By Product Type
   14.9 Market Attractiveness Analysis By Product Type
   14.10 Latin America Drugs for Herpes Labialis Market Size & Volume Forecast By Medication Type
      14.10.1 Prescribed
      14.10.2 OTC
   14.11 Basis Point Share (BPS) Analysis By Medication Type
   14.12 Absolute $ Opportunity Assessment By Medication Type
   14.13 Market Attractiveness Analysis By Medication Type
   14.14 Latin America Drugs for Herpes Labialis Market Size & Volume Forecast By Dosage Forms
      14.14.1 Ointments/Cream/Gels/Lip Balm
      14.14.2 Medicines
      14.14.3 Injections
   14.15 Basis Point Share (BPS) Analysis By Dosage Forms
   14.16 Absolute $ Opportunity Assessment By Dosage Forms
   14.17 Market Attractiveness Analysis By Dosage Forms
   14.18 Latin America Drugs for Herpes Labialis Market Size & Volume Forecast By Routes of Administration
      14.18.1 Topical
      14.18.2 Oral
      14.18.3 Parenteral
   14.19 Basis Point Share (BPS) Analysis By Routes of Administration
   14.20 Absolute $ Opportunity Assessment By Routes of Administration
   14.21 Market Attractiveness Analysis By Routes of Administration

Chapter 15 Middle East & Africa (MEA) Drugs for Herpes Labialis Analysis and Forecast
   15.1 Introduction
   15.2 Middle East & Africa (MEA) Drugs for Herpes Labialis Market Size Forecast by Country
      15.2.1 Saudi Arabia
      15.2.2 South Africa
      15.2.3 UAE
      15.2.4 Rest of Middle East & Africa (MEA)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Middle East & Africa (MEA) Drugs for Herpes Labialis Market Size & Volume Forecast By Product Type
      15.6.1 Aciclovir
      15.6.2 Valacyclovir
      15.6.3 Famciclovir
      15.6.4 Docosano
   15.7 Basis Point Share (BPS) Analysis By Product Type
   15.8 Absolute $ Opportunity Assessment By Product Type
   15.9 Market Attractiveness Analysis By Product Type
   15.10 Middle East & Africa (MEA) Drugs for Herpes Labialis Market Size & Volume Forecast By Medication Type
      15.10.1 Prescribed
      15.10.2 OTC
   15.11 Basis Point Share (BPS) Analysis By Medication Type
   15.12 Absolute $ Opportunity Assessment By Medication Type
   15.13 Market Attractiveness Analysis By Medication Type
   15.14 Middle East & Africa (MEA) Drugs for Herpes Labialis Market Size & Volume Forecast By Dosage Forms
      15.14.1 Ointments/Cream/Gels/Lip Balm
      15.14.2 Medicines
      15.14.3 Injections
   15.15 Basis Point Share (BPS) Analysis By Dosage Forms
   15.16 Absolute $ Opportunity Assessment By Dosage Forms
   15.17 Market Attractiveness Analysis By Dosage Forms
   15.18 Middle East & Africa (MEA) Drugs for Herpes Labialis Market Size & Volume Forecast By Routes of Administration
      15.18.1 Topical
      15.18.2 Oral
      15.18.3 Parenteral
   15.19 Basis Point Share (BPS) Analysis By Routes of Administration
   15.20 Absolute $ Opportunity Assessment By Routes of Administration
   15.21 Market Attractiveness Analysis By Routes of Administration

Chapter 16 Competition Landscape
   16.1 Drugs for Herpes Labialis Market: Competitive Dashboard
   16.2 Global Drugs for Herpes Labialis Market: Market Share Analysis, 2019
   16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
      16.3.1 Apotex Inc
      16.3.2 Pfizer INC
      16.3.3 Mylan N.V.
      16.3.4 Novartis AG
      16.3.5 Teva Pharmaceutical Industries Ltd
      16.3.6 Zydus Cadila
      16.3.7 Hikma Pharmaceuticals PLC
      16.3.8 Livzon
      16.3.9 Torrent Pharmaceuticals Ltd
      16.3.10 Blistex Inc